Welcome to our dedicated page for BlackRock Tech and Private Equity Term news (Ticker: BTX), a resource for investors and traders seeking the latest updates and insights on BlackRock Tech and Private Equity Term stock.
BlackRock Technology and Private Equity Term Trust (BTX) generates news and disclosures that focus on its role as a BlackRock-managed closed-end term trust with an equity investment strategy. Coverage often centers on the Fund’s managed distribution plan, tender offers for its common shares, and communications from its Board of Trustees regarding distribution policy and capital management.
Recent news has highlighted decisions by the Board of Trustees to update BTX’s managed distribution plan, including a shift from a floating rate distribution to a level rate distribution at a stated monthly rate. These announcements explain the rationale for the changes, such as enhancing distribution stability, maintaining a competitive distribution rate and managing the mix of public and private investments. News items also provide estimated allocations of distributions among net income, capital gains and return of capital, along with explanations of what return of capital means for shareholders and net asset value.
Another key theme in BTX news is corporate actions involving its capital structure. The Fund has announced the commencement, expiration, preliminary results and final results of a tender offer to repurchase up to 50% of its outstanding common shares at a price tied to net asset value. These releases describe the tender offer terms, the number of shares offered and tendered, and the pricing mechanism, while directing investors to the formal tender offer documents filed with the SEC.
Investors following BTX news can expect updates on distribution policies, estimates of distribution sources, tender offer activity, and references to where to find official reports and regulatory filings. Monitoring these announcements helps readers understand how the Fund’s Board manages distributions and capital actions within the framework of its investment objective and regulatory requirements.
BlackRock closed‑end funds BMEZ, BSTZ, BTX announced distribution plan updates effective with the October 2025 distribution cycle (declaration 9/10/2025; ex‑date and record 10/15/2025; payable 10/31/2025). Each fund moves from a floating rate to a level monthly distribution at stated per‑share amounts: BMEZ $0.11000, BSTZ $0.16250, BTX $0.05250.
Estimated allocation data as of 8/29/2025 show large portions of recent distributions characterized as return of capital (BMEZ and BTX ~100% ROC for the reported periods; BSTZ shows long‑term gains). Reported annualized distribution rates (as of 7/31/2025) are BMEZ 13.04%, BSTZ 11.37%, BTX 12.32%. Boards may amend or suspend plans and distributions affect NAV.
BlackRock announced significant updates to the managed distribution plans for three funds: BMEZ, BSTZ, and BTX. Starting October 2025, the funds will transition from floating rate to level rate monthly distributions. The new fixed monthly distributions are: $0.11 for BMEZ, $0.1625 for BSTZ, and $0.0525 for BTX.
The changes represent decreases from prior distributions and aim to enhance distribution stability while maintaining competitive rates. For the fiscal year through August 29, 2025, BMEZ and BTX distributions were entirely return of capital, while BSTZ distributions came from long-term capital gains. The funds' performance varies significantly, with BSTZ showing positive 5-year returns of 5.85%, while BMEZ and BTX reported negative returns of -0.18% and -11.19% respectively.
BlackRock Technology and Private Equity Term Trust (BTX) has announced the final results of its undersubscribed tender offer. The Fund will purchase all 96,627,850 shares that were properly tendered, representing less than the maximum 50% of outstanding shares (106,669,074) initially offered.
The purchase price is set at $7.4924 per share, which equals 99.5% of the Fund's net asset value as of July 9, 2025. Payment for the tendered shares is expected to be completed around July 16, 2025.
BlackRock Technology and Private Equity Term Trust (BTX) has announced the preliminary results of its tender offer that expired on July 8, 2025. The Fund offered to repurchase up to 106,669,074 shares (50% of outstanding common shares) at 99.5% of NAV as of July 9, 2025.
According to preliminary data, shareholders tendered 96,627,850 shares. Since the tender offer was undersubscribed, the Fund expects to purchase all properly tendered shares. Final results are expected to be announced on July 9, 2025.
BlackRock Technology and Private Equity Term Trust (NYSE: BTX) shareholders have approved two significant strategic changes during a Special Shareholder Meeting. The first change amends the Trust's fundamental investment restriction, allowing it to concentrate investments in companies within the technology group of industries. The second modification changes the Trust's status from diversified to non-diversified under the Investment Company Act of 1940.
Brooklyn ImmunoTherapeutics is rebranding as Eterna Therapeutics, effective October 17, 2022, to focus on mRNA cell engineering therapies. This shift reflects the acquisition of an extensive patent portfolio through in-licensing agreements, including over 100 patents for key cell engineering technologies. Concurrently, the company will initiate a one-for-twenty share consolidation and trade under the new ticker symbol ERNA. Eterna aims to advance its therapeutic pipeline via strategic partnerships as it transitions to a platform company in cellular and gene editing.
BROOKLYN, July 26, 2022 – Brooklyn ImmunoTherapeutics (Nasdaq: BTX) announces results from the INSPIRE phase 2 trial of IRX-2, an immunotherapy for stage II, III, or IVA squamous cell carcinoma of the oral cavity. With 150 patients enrolled, the trial reported a median Event-Free Survival (EFS) of 48.3 months in the treatment arm, exceeding the control arm. Safety profiles showed higher adverse events in the treatment group (55.9% vs 40%). The findings indicate a potential benefit for patients not receiving chemotherapy, particularly those with advanced disease. The company plans to present these results at an upcoming conference.
Brooklyn ImmunoTherapeutics (Nasdaq:BTX) announced on June 17, 2022, that it received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share. The company has 180 days until December 14, 2022, to regain compliance by achieving a minimum bid price of $1.00 for 10 consecutive business days. The notice does not immediately affect trading. Brooklyn is actively monitoring its stock price and considering options for compliance.
Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) announced the appointment of four new board members effective June 5, 2022, as part of its strategic growth plan. The new members include Matt Angel, Ph.D., Gregory Fiore, MD, Nicholas Singer, and Bill Wexler, who bring extensive experience in biotechnology and finance. This transition follows the departure of four previous board members. The company aims to advance its initiatives in cytokine, gene editing, and cell therapy for cancer and genetic diseases, positioning itself for future growth.